Please upgrade your browser.
The highest response rates were observed in patients with a high Fuhrman grade or sarcomatoid features (22%), grade 4 tumors (25%), or sarcomatoid histology (33%). Overall, 46% of patients had some degree of tumor shrinkage, the authors reported.
“The news that Eisai has submitted this application is hugely positive, for both clinicians and patients alike. The current outlook for people with this aggressive cancer is poor, and therefore the potential of lenvatinib is very exciting indeed.” - See more at: http://www.onclive.com/web-exclusives/lenvatinib-everolimus-combo-submitted-for-approval-in-advanced-rcc#sthash.nJ74LEgg.dpuf
In a poster presentation entitled “The Anti-Cancer Effects of Supinoxin (RX-5902) in Renal Cell Cancer,” Rexahn scientists detailed the results of several preclinical studies showing the antiproliferative effects of Supinoxin in various human renal cancer cell lines and xenograft renal cancer models.
The number of patients with renal cancer in Europe is estimated to be 115,000,1 and renal cell carcinoma comprises more than 90% of all malignancies of the kidney.2 For advanced or metastatic renal cell carcinoma that is difficult to treat with surgery, the standard treatment method is molecular targeted drug therapy, however with low 5-year survival rates, this remains a disease with significant unmet medical need.
His abstract was recognized as a Top Poster in the track.
Dr. Toni Choueiri, of Dana Farber, presents highlights from ASCO GU 2016 Genitourinary Symposium held in San Francisco
The number of new cancer diagnoses in the U.S. is largely steady while the number of cancer deaths continues to decline, according to a new report from the nation's leading cancer advocacy group.
Discontinuing VEGF-targeted therapy for progression or toxicity affects outcomes of second-line therapies in mRCC
Dr de Velasco talks to ecancertv at ASCO GU 2016 about analysing when VEGF-targeted therapy for metastatic renal cell carcinoma (mRCC) is discontinued.
Exelixis announced that it has completed the submission of its rolling New Drug Application (NDA) with the Food and Drug Administration (FDA) and requested Priority Review for cabozantinib (tablet formulation) as a treatment for patients with advanced renal cell carcinoma (RCC) who have received one prior therapy.
HealthWell fund will provide financial assistance to under-insured patients with renal cell carcinoma.
|Powered by NeonCRM|